Rene Sindlev Boosts Renovaro Biosciences Stake to 19.9%

TL;DR

**Rene Sindlev now owns 19.9% of Renovaro Biosciences, a big chunk!**

AI Summary

Rene Sindlev, a significant shareholder in Renovaro Biosciences Inc. (formerly Enochian Biosciences Inc.), filed an amended Schedule 13D/A on January 24, 2024. This amendment updates his beneficial ownership, indicating he now holds 10,000,000 shares of common stock, representing 19.9% of the company's outstanding shares. This matters to investors because Sindlev's substantial stake gives him considerable influence over the company's strategic decisions and future direction, potentially impacting stock performance.

Why It Matters

A major shareholder increasing their stake often signals confidence in the company's future, but it also means a single individual has significant control over the company's direction.

Risk Assessment

Risk Level: medium — While increased insider ownership can be positive, a single individual holding nearly 20% of shares introduces concentration risk and potential for unilateral decision-making.

Analyst Insight

Investors should monitor future filings by Rene Sindlev for any further changes in his ownership, as well as any corporate actions that may reflect his influence. This significant stake could lead to strategic shifts or M&A activity.

Key Numbers

• 10,000,000 — Shares Beneficially Owned (Number of common shares Rene Sindlev beneficially owns in Renovaro Biosciences Inc.)
• 19.9% — Percentage of Class (Rene Sindlev's beneficial ownership percentage of Renovaro Biosciences Inc. common stock.)
• 20240124 — Filing Date (Date the SC 13D/A amendment was filed.)
• 236078101 — CUSIP Number (Identifier for Renovaro Biosciences Inc. Common Stock.)

Key Players & Entities

• Rene Sindlev (person) — Reporting Person and significant shareholder of Renovaro Biosciences Inc.
• Renovaro Biosciences Inc. (company) — The Issuer of the securities, formerly Enochian Biosciences Inc.
• 03 Life Sciences (company) — Organization Name associated with the subject company.
• RS GROUP APS (company) — Group Member associated with the filing.
• $0.0001 (dollar_amount) — Par value per share of Renovaro Biosciences Inc. Common Stock.

Forward-Looking Statements

• Rene Sindlev will likely exert significant influence over Renovaro Biosciences' strategic decisions due to his substantial ownership stake. (Rene Sindlev) — high confidence, target: 2025-01-24
• The company's stock price may react positively to the increased insider ownership, signaling confidence. (Renovaro Biosciences Inc.) — medium confidence, target: 2024-04-24

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• e5371_sc13da1.htm (SC 13D/A) — 52KB
• e5371_ex-1.htm (EX-1) — 5KB
• 0001731122-24-000135.txt ( ) — 59KB

Security and Issuer

Item 1. Security and Issuer This Schedule 13D relates to the common stock, par value $0.0001 per share (the “ Common Stock ”) of the Renovaro Biosciences Inc. (previously known as Enochian Biosciences Inc. and at the time of the reported transaction, DanDrit BioTech USA, Inc.), whose principal executive offices are located at 2080 Century City East, Suite 906, Los Angeles, CA 90067. Item 2. Identity and Background

(a), (b), (c) and (f)

Item 2(a), (b), (c) and (f) are hereby amended and modified to include the following (which shall be in addition to the information previously included in the Prior 13D): RS Group ApS, whose principal address Stumpedyssevej 17, 2970 Horsholm, Denmark and which is a Danish company. Rene Sindlev, whose principal address is Stumpedyssevej 17, 2970 Horsholm, Denmark. Mr. Sindlev is a Danish citizen.

(d) is hereby amended and restated, in its

Item 2(d) is hereby amended and restated, in its entirety, as follows: (d) No Reporting Person has during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). To the knowledge of the Reporting Persons, no person specified by Instruction C has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) is hereby amended and restated, in its

Item 2(e) is hereby amended and restated, in its entirety, as follows: (e) No Reporting Person, during the last five years, was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities Item 4. Purpose of the Transaction

is hereby amended and

Item 4 is hereby amended and modified to include the following (which shall be in addition to the information previously included in the Prior 13D): This Amendment is being filed to report the purchase of additional securities of the Issuer by RS Group ApS and to include Rene Sindlev as a Reporting Person. On March 14, 2016, RS Group ApS purchased 555,869 shares of the Issuer’s common stock.

Interest

Item 5. Interest in Securities of the Issuer

is hereby amended and

Item 5 is hereby amended and modified to include the following: (a) and (b). The responses of the Reporting Person to rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Statement are incorporated herein by reference. Mr. Sindlev has the sole power to direct the voting and/or disposition of the shares of Common Stock owned by RS Group ApS. (c) Other than as reported on the Prior 13D, the Reporting Persons have not effected any transactions in the Common Stock in the last 60 days.

Material

Item 7. Material to be Filed as Exhibits Exhibit 1Joint Filing Agreement SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 24, 2024 /s/ Rene Sindlev Rene Sindlev RS GROUP APS By: /s/ Rene Sindlev Name: Rene Sindlev Title: Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR